Company profile for IFM Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At IFM Therapeutics, LLC, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response. IFM Therapeutics, LLC was formed following the acquisition of IFM Therapeutics by Bristol-Myers Squibb in 2017. IFM Therapeutics, LLC retained its personnel and facilitie...
At IFM Therapeutics, LLC, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response. IFM Therapeutics, LLC was formed following the acquisition of IFM Therapeutics by Bristol-Myers Squibb in 2017. IFM Therapeutics, LLC retained its personnel and facilities, as well as its remaining research programs focused on curbing immune responses that lead to inflammatory diseases and fibrosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
855 Boylston Street, 11th Floor, Boston, MA 02116
Telephone
Telephone
+1-857-304-0583
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/serial-entrepreneur-gary-glick-sells-another-one-of-his-startups-for-290m-this-time-to-an-unlikely-buyer/

ENDPTS
13 Sep 2021

https://www.prnewswire.com/news-releases/ifm-therapeutics-announces-55-5-million-financing-to-launch-and-fund-new-subsidiaries-and-appointment-of-dr-h-martin-seidel-as-chief-executive-officer-300967030.html

PR NEWSWIRE
02 Dec 2019

https://www.fiercebiotech.com/biotech/ifm-gets-new-ceo-bags-another-55m-to-launch-incubator-new-subsidiaries

A. A Idrus FIERCE BIOTECH
02 Dec 2019

https://www.prnewswire.com/news-releases/ifm-therapeutics-announces-55-5-million-financing-to-launch-and-fund-new-subsidiaries-and-appointment-of-dr-h-martin-seidel-as-chief-executive-officer-300967030.html

PRNEWSWIRE
02 Dec 2019

https://www.prnewswire.com/news-releases/new-research-demonstrates-second-direct-link-between-inflammasome-activation-and-alzheimers-disease-300962374.html

PR NEWSWIRE
21 Nov 2019
Novartis, IFM Due ink R&D deal—with $840M buyout option
Novartis, IFM Due ink R&D deal—with $840M buyout option

06 Sep 2019

// Amirah.A. Drus FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/novartis-bankrolls-ifm-due-s-cgas-sting-pipeline-840m-buyout-option

Amirah.A. Drus FIERCE BIOTECH
06 Sep 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty